Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-17T14:42:57.463Z Has data issue: false hasContentIssue false

The Value of Collaboration in Improving Knowledge on Rare Diseases

Published online by Cambridge University Press:  02 December 2014

Kate Bushby*
Affiliation:
Newcastle-upon-Tyne, United Kingdom
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1 Mah, JK, Selby, K, Campbell, C, et al. A population-based study of dystrophin mutations in Canada. Can J Neurol Sci. 2011;38(3): 465–74.CrossRefGoogle ScholarPubMed
2 Bushby, K, Finkel, R, Birnkrant, DJ, et al. Diagnosis and management of DuchenneMuscular Dystrophy, part 1: diagnosis and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):7793.CrossRefGoogle Scholar
3 Bushby, K, Lochmuller, H, Lynn, S, Straub, V. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet. 2009;374(9704):1849–56.CrossRefGoogle ScholarPubMed
4 Cunnif, C, Andrews, J, Meaney, FJ, et al. Mutation analysis in a population based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol. 2009;24(4):425–30.CrossRefGoogle Scholar
5 Abbs, S, Tuffery-Giraud, S, Bakker, E, Ferlini, A, Sejersen, T, Mueller, CR. Best practice guidelines on molecular testing in Duchenne and Becker muscular dystrophies. Neuromuscul Disord. 2010 Jun;20(6):422–7.CrossRefGoogle Scholar